Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17834060 | 1.00 | SHBG (0.52) | SHBGTP53KDM4EGMNNLMNA | |
| SCHEMBL24920002 | 0.87 | — | — | |
| SCHEMBL10077547 | 0.84 | SHBG (0.56) | SHBGTP53KDM4EGMNNLMNA | |
| SCHEMBL17834061 | 0.82 | SHBG (0.48) | SHBGTP53KDM4EGMNNLMNA | |
| SCHEMBL27154294 | 0.82 | SHBG (0.43) | SHBGTP53KDM4EGMNNLMNA | |
| SCHEMBL12833188 | 0.79 | SHBG (0.44) | SHBGTP53KDM4EGMNNLMNA | |
| SCHEMBL12832711 | 0.79 | SHBG (0.44) | SHBGTP53KDM4EGMNNLMNA | |
| SCHEMBL22068456 | 0.78 | SHBG (0.76) | SHBGTP53KDM4EGMNNLMNA | |
| SCHEMBL11802672 | 0.78 | SHBG (0.76) | SHBGTP53KDM4EGMNNLMNA | |
| SCHEMBL21785851 | 0.77 | PIK3CD (0.35) | SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8961946-B2 | Hair processing agent and method for permanent waving hair | SHOWA DENKO K.K. (JP) | 2015-02-24 | — | — | US | disclosed |
| CN-101669887-B | Hair processing agent and method for permanent waving hair | SHOWA DENKO KK | 2012-12-05 | — | — | CN | disclosed |
| CN-101083975-B | Hair treatment agent and hair waving method | SHOWA DENKO KK | 2010-12-01 | — | — | CN | disclosed |
| CN-101669887-A | Hair processing agent and method for permanent waving hair | SHOWA DENKO KK | 2010-03-17 | — | — | CN | disclosed |
| US-20080085251-A1 | even at a neutral to weakly acidic pH; a lactone or lactam having a mercapto group; with thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine; | RESONAC CORPORATION (JP) | 2008-04-10 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332488-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| CN-101083975-A | Hair treatment agent and hair waving method | SHOWA DENKO KK (JP) | 2007-12-05 | — | — | CN | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-05-24 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SHBG 875/4885TP53 3589/4885KDM4E 3314/4885 |
| US-20080085251-A1 | even at a neutral to weakly acidic pH; a lactone or lactam having a mercapto group; with thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine; | TST, CYSLTR1, CYSLTR2 | SHBG 402/4885TP53 1570/4885KDM4E 4747/4885 |
| US-20070117795-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | SHBG 875/4885TP53 3589/4885KDM4E 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.